Insulin underdelivery from implanted pumps using peritoneal route: Determinant role of insulin pump compatibility

Diabetes Care

Volumn 19, Issue 8, 1996, Pages 812-817

  Renard, Eric ^a   Bouteleau, Serge ^a   Jacques Apostol, Dominique ^a   Lauton, Dominique ^a   Gibert Boulet, Françoise ^a   Costalat, Guy ^a   Bringer, Jacques ^a   Jaffiol, Claude ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRAL INSULIN;

ARTICLE; CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; IMPLANTATION; INSULIN INFUSION; INSULIN PUMP; INSULIN TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; TREATMENT FAILURE;

EID: 0029799449     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.8.812     Document Type: Article

References (32)

1. Point Study Group: One-year trial of a remote-controlled implantable insulin infusion system in type I diabetic patients. Lancet i:864-869, 1988
2. Saudek CD, Selam JL, Put HA, Waxman K, Rubio M, Jeandidier N, Turner D, Fishell RE, Charles MA: A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Md 321:574-579, 1989
3. Selam JL, Micossi P, Dunn FL, Nathan DM: Clinical trial of programmable implantable insulin pumps for type 1 diabetes. Diabetes Care 15:877-885, 1992
4. Renard E, Lauton D, Bonifacj C, Costalat G, Jacques D, Bringer J, Jaffiol C: Experience with intraperitoneal insulin infusion from implantable programmable systems in type I (insulin-dependent) diabetes mellitus previously treated by external pumps. Diabete Metab 19:364-371, 1993
5. Hanaire-Broutin H, Broussolle C, Jeandidier N, Renard E, Guerci B, Haardt MJ, Lassmann-Vague V, the EVADIAC Study Group: Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: a multicenter study. Diabetes Care 18:388-392, 1995
6. Broussolle C, Jeandidier N, Hanaire-Broutin H, the EVADIAC Study Group: French multicenter experience of implantable insulin pumps. Lancet 343: 514-515, 1994
7. Selam JL, Raccah D, Jeandidier N, Lozano JL, Waxman K, Charles MA: Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type 1 diabetic patients. Diabetes Care 15:53-58, 1992
8. Nelson JA, Stephen R, Landau ST, Wilson DE, Tyler FH: Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized, unrestrained swine. Metabolism 31:969-972, 1982
9. Olsen CL, Turner DS, Iravani M, Waxman K, Selam JL, Charles MA: Diagnostic procedures for catheter malfunction in programmable implantable intraperitoneal insulin infusion devices. Diabetes Care 18: 70-76, 1995
10. Renard E, Baldet P, Picot MC, Jacques-Apostol D, Lauton D, Costalat G, Bringer J, Jaffiol C: Catheter complications associated with implantable systems for peritoneal insulin delivery: an analysis of frequency, predisposing factors, and obstructing materials. Diabetes Care 18: 300-306, 1995
11. Grau U, Saudek CD: Stable insulin preparation for implanted insulin pumps: laboratory and animal trials. Diabetes 36:1453-1459, 1987
12. Lougheed WD, Woulle-Flanagan H, Clement JR, Albisser AM: Insulin aggregation in artificial delivery systems. Diabetologia 19:1-9, 1980
13. Schade DS, Eaton RP, Spencer W: Implantation of an artificial pancreas: current perspectives. JAMA 245:709-710, 1981
14. Selam JL, Charles MA: Devices for insulin administration. Diabetes Care 13:955-979, 1990
15. Gerhard H, Schulz A, Hogan M: Problems of insulin precipitations in implanted insulin infusion pumps (Abstract). Diabetes 34 (Suppl. 1):199A, 1985
16. Martindale H, Marsh J, Hallett FR, Albisser AM: Examination of insulin formulations using quasi-elastic light scattering. Diabetes 31:364-366, 1982
17. Lougheed WD, Albisser AM, Martindale HM, Chow JC, Clement JR: Physical stability of insulin formulations. Diabetes 32: 424-432, 1983
18. Pongor S, Brownlee M, Cerami A: Preparations of high-potency, non-aggregating insulins using a novel sulfation procedure. Diabetes 32:1087-1091, 1983
19. Albisser AM, Lougheed WD, Perlman K, Bahoric A: Nonaggregating insulin solutions for long-term glucose control in experimental and human diabetes. Diabetes 29:241-243, 1980
20. Bringer J, Heldt A, Grodsky GM: Prevention of insulin aggregation by dicarboxylic amino acids during prolonged infusion. Diabetes 30:83-85, 1981
21. Lougheed WD, Fischer U, Perlman K, Albisser AM: A physiological solvent for crystalline insulin. Diabetologia 20:51-53, 1981
22. Brange J, Havelund S: Insulin pumps and insulin quality: requirements and problems. Acta Med Scand 671 (Suppl.):135-138, 1983
23. Blackshear PJ, Ronde TD, Palmer JL, Wigness BD, Rupp WM, Buchwald H: Glycerol prevents insulin precipitation and interruption of flow in an implantable insulin infusion pump. Diabetes Care 6:387-392, 1983
24. Chawla AS, Hinberg I, Blais P, Johnson D: Aggregation of insulin, containing surfactants, in contact with different materials. Diabetes 34:420-424, 1985
25. Waugh DF, Wilhelmson DF, Commerford SL, Sackler ML: Studies of the nucleation and growth reactions of selected types of insulin fibrils. J Am Chem Soc 75: 2592-2595, 1953
26. Sefton MV, Antonacci GM: Adsorption isotherms of insulin onto various materials. Diabetes 33:674-680, 1984
27. Grau U: Chemical stability of insulin in a delivery system environment. Diabetologia 28:458-463, 1985
28. Grau U: Insulin stability. In Continuous Insulin Infusion Therapy: Experience From One Decade. Hepp KD, Renner R, Eds. Stuttgart. Germany, Schattauer, 1985, p. 33-46
29. Olsen CL, Chan E, Turner D, Iravani M, Nagy M, Selam JL, Wong N, Charles MA: Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care 17:169-176, 1994
30. Lassmann-Vague V, Belicar P, Raccah D, Vialettes B, Sodoyez JC, Vague P: Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps: metabolic consequences. Diabetes Care 18:498-503, 1995
31. Jeandidier N, Boivin S, Sapin R, Rosart-Ortega F, Uring-Lambert B, Réville P, Pinget M. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38:577-584, 1995
32. Robbins DC, Cooper SM, Fineberg SE, Mead PM: Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36:838-841, 1987